Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT05347212
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Carcinomas
  • Renal Medullary Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To learn if the combination of nivolumab and relatlimab can help to control renal medullary carcinoma (RMC) that is locally advanced or metastatic (has spread).

Key Dates

Start date
Sep 22, 2022
Status verified
Apr 2026
Primary completion
Jul 16, 2027
Completion
Jul 16, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nivolumab+Relatlimab
    nivolumab 480 mg IV plus relatlimab 480 mg IV every 4 weeks for up to 2 years

Primary Outcome Measure

To establish the objective response rate (ORR) of patients with locally advanced or metastatic RMC treated with combination nivolumab plus relatlimab. [ Time Frame: through study completion, an average of 2 year ]

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By research site
MD Anderson Cancer Center· Houston, TX

Related Studies